Takeda, an international pharmaceutical company, actively promotes development and manufacturing of innovative oncological drugs. This vector of activities is one of the main ones for the company. In the near future, the company will localize the manufacturing of several innovative products in Russia.
A monoclonal antibody conjugated with a cytostatic agent is an innovative targeted drug for the treatment of Hodgkin lymphoma that can specifically target the tumor cells. The first lots of the localized drug will arrive to the Russian market in H2 2018. The transfer of manufacturing to Russia will not only increase the availability of the drug for patients but, in the long run, will also contribute to reducing its price compared to the reference countries.
The second antitumor drug of Takeda registered in Russia is a medicine for the treatment of multiple myeloma. This is the first Once-a-Week Tablet product. Now, the patients diagnosed with multiple myeloma will have a chance to extend their life without facing the progression of the disease and without changing the usual pace of their life. The manufacturing of this drug will be localized at the plant in Yaroslavl, and the transfer of full-cycle manufacturing technology is already underway.
In the future, there will be new drugs for the treatment of lung cancer and breast cancer. In the long term, the company plans to design new innovative forms of drugs for the treatment of malignant neoplasms.